Tonix Pharmaceuticals stock halted ahead of FDA approval news
LONDON - Fusion Antibodies plc (AIM:LON:FAB), a company specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications, has announced an upcoming live investor presentation. Scheduled for Thursday, May 22 at 11:30 am, the event will feature CEO Dr. Adrian Kinkaid and interim CFO Stephen Smyth, and will accompany the firm’s recent trading update for the fiscal year 2025.
The presentation aims to provide both current and prospective investors with direct insights from the management team regarding the company’s latest financial performance. It will be accessible through the digital platform Investor Meet Company (IMC).
Investors interested in attending can register for free on the IMC website and add Fusion Antibodies plc to their list to receive an automatic invitation. Participants will have the opportunity to submit questions before the event through their IMC dashboard or in real-time during the presentation using the "Ask a Question" feature. While not all questions may be addressed, the company intends to respond to the most pertinent inquiries within the scope of information already made public through regulatory announcements.
Following the live event, a recording of the presentation, the slides used, and the responses to the question-and-answer session will be made available on the Investor Meet Company platform.
This initiative by Fusion Antibodies plc is part of its commitment to maintaining open communication with its investment community and ensuring transparency about its financial updates and strategic direction. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.